Year of investment: 2023
About the company:

Sentante is an innovative teleoperated robotic system developed by UAB Inovatyvi Medicina. It allows an entire endovascular intervention to be performed remotely, from a different room, so physicians and the entire medical team can work without being exposed to harmful X-ray radiation. In the future, Sentante will allow physicians to perform endovascular treatment from a remote hospital, eliminating the need for physical patient transfer. This innovation bears profound significance, particularly in critical cases such as stroke, where each passing minute significantly impacts the chances of a good outcome. 


Categories: MedTech, Medical Device;

Founded: 2017

Founder(s): Dr. Evaldas Kalvaitis, Dr. Tomas Baltrunas, Edvardas Satkauskas, Vaidas Labunskas, Vilius Dambrauskas

Location(s): Kaunas, Lithuania

Entry date: 2023

Entry-stage: Seed

Latest stage: Seed

Latest round: Seed

Co-investors: European Innovation Council Fund

Exit: n/a


Sentante Secures €6 Million in New Funding to Revolutionize Endovascular Care

Back to the list